FR08C0013I2 - Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer - Google Patents

Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer

Info

Publication number: FR08C0013I2
Authority: FR; France
Prior art keywords: dexamethasone; combination therapy; treat cancer; cancer; treat
Prior art date: 1999-05-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR08C0013C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmamar SA

Original Assignee

Pharmamar SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-13

Filing date

2008-04-16

Publication date

2009-10-30

1999-05-13 Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en

1999-05-14 Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en

1999-08-05 Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en

1999-11-15 Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en

1999-11-16 Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en

2000-03-29 Priority claimed from GB0007637A external-priority patent/GB0007637D0/en

2008-04-16 Application filed by Pharmamar SA filed Critical Pharmamar SA

2008-05-30 Publication of FR08C0013I1 publication Critical patent/FR08C0013I1/fr

2009-10-30 Application granted granted Critical

2009-10-30 Publication of FR08C0013I2 publication Critical patent/FR08C0013I2/fr

Status Active legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
238000002648 combination therapy Methods 0.000 title 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 title 1
229960003957 dexamethasone Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

FR08C0013C 1999-05-13 2008-04-16 Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer Active FR08C0013I2 (fr)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
GBGB9911183.3A GB9911183D0 (en)	1999-05-13	1999-05-13	Treatment of cancers
GBGB9911346.6A GB9911346D0 (en)	1999-05-14	1999-05-14	Treatment of cancers
GBGB9918534.0A GB9918534D0 (en)	1999-08-05	1999-08-05	Treatment of cancers
GBGB9927005.0A GB9927005D0 (en)	1999-11-15	1999-11-15	Treatment of cancers
GBGB9927106.6A GB9927106D0 (en)	1999-11-16	1999-11-16	Cancer treatment
GB0007637A GB0007637D0 (en)	2000-03-29	2000-03-29	Antitumour compound
EP00927584A EP1176964B8 (fr)	1999-05-13	2000-05-15	Utilisation du compose et743 pour le traitement du cancer

Publications (2)

Publication Number	Publication Date
FR08C0013I1 FR08C0013I1 (fr)	2008-05-30
FR08C0013I2 true FR08C0013I2 (fr)	2009-10-30

Family

ID=27546594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR08C0013C Active FR08C0013I2 (fr)	1999-05-13	2008-04-16	Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer

Country Status (32)

Country	Link
US (1)	US8119638B2 (fr)
EP (3)	EP1716853B9 (fr)
JP (2)	JP2002544231A (fr)
KR (1)	KR20020019914A (fr)
CN (2)	CN1360503A (fr)
AR (1)	AR028476A1 (fr)
AT (3)	ATE500830T1 (fr)
AU (2)	AU777417B2 (fr)
BG (1)	BG65680B1 (fr)
BR (1)	BR0010531A (fr)
CA (1)	CA2373794C (fr)
CY (4)	CY1105818T1 (fr)
CZ (1)	CZ301482B6 (fr)
DE (4)	DE122008000013I1 (fr)
DK (3)	DK1176964T3 (fr)
ES (2)	ES2272279T3 (fr)
FR (1)	FR08C0013I2 (fr)
HU (2)	HU229866B1 (fr)
IL (2)	IL146434A0 (fr)
LU (1)	LU91418I2 (fr)
MX (1)	MXPA01011562A (fr)
MY (1)	MY164077A (fr)
NL (1)	NL300337I2 (fr)
NO (2)	NO324564B1 (fr)
NZ (1)	NZ515423A (fr)
PL (1)	PL198185B1 (fr)
PT (3)	PT1176964E (fr)
SI (3)	SI1176964T1 (fr)
SK (1)	SK287580B6 (fr)
TR (1)	TR200103819T2 (fr)
UA (1)	UA74782C2 (fr)
WO (1)	WO2000069441A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY164077A (en)	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
MXPA02011319A (es)	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
EA005564B1 (ru) *	2000-11-06	2005-04-28	Фарма Мар, С.А.	Эффективные противоопухолевые лекарственные средства
GB0117402D0 (en) *	2001-07-17	2001-09-05	Pharma Mar Sa	New antitumoral derivatives of et-743
KR20050038578A (ko) *	2001-10-19	2005-04-27	파르마 마르, 에스.에이.	항종양성 화합물의 암치료에 있어서의 향상된 용도
GB0202544D0 (en)	2002-02-04	2002-03-20	Pharma Mar Sa	The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
GB0324201D0 (en) *	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
SI1689404T1 (sl) *	2003-11-13	2009-02-28	Pharma Mar Sau	Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
CN1897949A (zh) *	2003-11-14	2007-01-17	马尔药品公司	包含使用et－743和紫杉醇来治疗癌症的联合疗法
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
AU2005261860A1 (en) *	2004-07-09	2006-01-19	Pharma Mar, S.A.	Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
RU2359700C2 (ru) *	2004-10-26	2009-06-27	Фарма Мар С.А., Сосьедад Униперсональ	Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
KR101188691B1 (ko) *	2004-10-29	2012-10-09	파르마 마르 에스.에이.	엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) *	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
MX2008014404A (es) *	2006-05-12	2008-11-27	Pharma Mar Sa	Tratamientos anticancer con combinacion de docetaxel y ecteinascidin.
CA2703026A1 (fr) *	2007-10-19	2009-04-23	Rafael Rosell Costa	Marqueurs moleculaires pronostiques pour le traitement par et-743
AU2017215603A1 (en) *	2016-02-04	2018-08-09	Jiangsu Hengrui Medicine Co., Ltd.	Trabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and method for manufacturing the same
US11332480B2 (en)	2017-04-27	2022-05-17	Pharma Mar, S.A.	Antitumoral compounds
WO2020239478A1 (fr)	2019-05-28	2020-12-03	Pharma Mar, S.A.	Trabectédine pour le traitement de sarcomes basé sur des marqueurs génomiques
CN112574234B (zh) *	2019-09-27	2022-05-24	江苏恒瑞医药股份有限公司	一种海鞘素衍生物的制备方法
BR112022020812A2 (pt)	2020-04-15	2022-11-29	Ever Valinject Gmbh	Composição farmacêutica compreendendo trabectedina e um aminoacido, formulação liofilizada e uma solução de injeção intravenosa compreendendo dita composição
EP3960177A1 (fr) *	2020-08-26	2022-03-02	Anturec Pharmaceuticals GmbH	Composition comprenant un ttf-ngr pour une utilisation dans le traitement du sarcome des tissus mous
AU2022277799A1 (en) *	2021-05-19	2023-12-21	Pharma Mar, S.A.	Dosage regimens for ecubectedin
US12303506B2 (en)	2022-01-20	2025-05-20	Extrovis Ag	Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5089273A (en)	1986-06-09	1992-02-18	Board Of Trustees Of The University Of Illinois	Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) *	1990-11-30	1992-09-22	The Board Of Trustees Of The University Of Illinois	Ecteinascidins 736 and 722
US5256663A (en) *	1986-06-09	1993-10-26	The Board Of Trustees Of The University Of Illinois	Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
AU589282B2 (en) *	1986-06-09	1989-10-05	University Of Illinois	Ecteinascidins 729, 743, 745, 759a, 759b and 770
DE3635711A1 (de)	1986-10-21	1988-04-28	Knoll Ag	5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) *	1988-03-04	1988-04-07	Glaxo Group Ltd	Medicaments
GB9101221D0 (en) *	1991-01-19	1991-02-27	Smithkline Beecham Plc	Pharmaceuticals
US5721352A (en)	1991-02-19	1998-02-24	University Of Florida Research Foundation	Entomopoxvirus expression system
FR2697752B1 (fr)	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) *	1992-11-19	1999-04-06	Anticancer, Inc.	Method to produce high levels of methioninase
WO1994026250A1 (fr) *	1993-05-14	1994-11-24	Depotech Corporation	Procede de traitement de troubles neurologiques
US5478932A (en) *	1993-12-02	1995-12-26	The Board Of Trustees Of The University Of Illinois	Ecteinascidins
US20040059112A1 (en)	1994-02-18	2004-03-25	Rinehart Kenneth L.	Ecteinascidins
US5919816A (en) *	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en)	1995-04-20	1995-06-07	Univ British Columbia	Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) *	1996-09-18	1998-02-24	President And Fellows Of Harvard College	Process for producing ecteinascidin compounds
DE69734290T2 (de) *	1996-11-05	2006-07-06	The Children's Medical Center Corp., Boston	Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
IL123740A0 (en) *	1997-03-28	1998-10-30	Pfizer	NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en)	1997-04-15	1999-11-16	Univ Illinois	Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) *	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) *	1997-06-05	1998-03-18	Merck & Co Inc	A method of treating cancer
CZ301083B6 (cs)	1998-04-06	2009-11-04	The Board Of Trustees Of The University Of Illinois	Ekteinascidinová sloucenina, farmaceutický prostredek ji obsahující a její použití
KR100643092B1 (ko) *	1998-05-11	2006-11-10	파르마 마르, 에스.에이.	엑테인아시딘 743의 대사산물
US6124292A (en)	1998-09-30	2000-09-26	President And Fellows Of Harvard College	Synthetic analogs of ecteinascidin-743
MY164077A (en)	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
AR035842A1 (es)	1999-05-14	2004-07-21	Pharma Mar Sa	Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
JP5219323B2 (ja)	2000-04-12	2013-06-26	ファルマ・マール・ソシエダード・アノニマ	抗腫瘍性エクチナサイジン誘導体
US7247892B2 (en)	2000-04-24	2007-07-24	Taylor Geoff W	Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es)	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en)	2000-05-15	2008-09-02	Pharma Mar, S.A.	Synthetic process for the manufacture of an ecteinaschidin compound
US20020137663A1 (en)	2000-08-11	2002-09-26	Forman Barry M.	The anti-neoplastic agent ET-743 inhibits trans activation by SXR
EA005564B1 (ru)	2000-11-06	2005-04-28	Фарма Мар, С.А.	Эффективные противоопухолевые лекарственные средства
EP1360337A1 (fr)	2001-02-09	2003-11-12	The Regents Of The University Of California	Composes de la famille de l'ecteinascidine: compositions et procedes
US20030027799A1 (en)	2001-03-30	2003-02-06	Shire Biochem Inc.	Methods of treating cancer using a combination of drugs
GB0121285D0 (en)	2001-09-03	2001-10-24	Cancer Res Ventures Ltd	Anti-cancer combinations
KR20050038578A (ko)	2001-10-19	2005-04-27	파르마 마르, 에스.에이.	항종양성 화합물의 암치료에 있어서의 향상된 용도
US20040019027A1 (en)	2002-04-12	2004-01-29	Barry Forman	Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en)	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
GB0324201D0 (en)	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
SI1689404T1 (sl)	2003-11-13	2009-02-28	Pharma Mar Sau	Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
GB0326486D0 (en)	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
CN1897949A (zh)	2003-11-14	2007-01-17	马尔药品公司	包含使用et－743和紫杉醇来治疗癌症的联合疗法
AU2005261860A1 (en)	2004-07-09	2006-01-19	Pharma Mar, S.A.	Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
AU2005288696A1 (en)	2004-09-28	2006-04-06	Pharma Mar S.A., Sociedad Unipersonal	Ecteinascidin compounds as anti -inflammatory agents
RU2359700C2 (ru)	2004-10-26	2009-06-27	Фарма Мар С.А., Сосьедад Униперсональ	Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
KR101188691B1 (ko)	2004-10-29	2012-10-09	파르마 마르 에스.에이.	엑티나시딘 및 디사카라이드를 포함하는 제제
DE602006020335D1 (de)	2005-11-25	2011-04-07	Pharma Mar Sa	Verwendung von parp-1-hemmern
MX2008014404A (es)	2006-05-12	2008-11-27	Pharma Mar Sa	Tratamientos anticancer con combinacion de docetaxel y ecteinascidin.

2000
- 2000-05-13 MY MYPI20002107A patent/MY164077A/en unknown
- 2000-05-15 AR ARP000102321A patent/AR028476A1/es not_active Application Discontinuation
- 2000-05-15 DE DE122008000013C patent/DE122008000013I1/de active Pending
- 2000-05-15 CA CA002373794A patent/CA2373794C/fr not_active Expired - Lifetime
- 2000-05-15 IL IL14643400A patent/IL146434A0/xx active IP Right Grant
- 2000-05-15 JP JP2000617900A patent/JP2002544231A/ja not_active Withdrawn
- 2000-05-15 EP EP06014005A patent/EP1716853B9/fr not_active Expired - Lifetime
- 2000-05-15 DE DE60030554T patent/DE60030554T8/de active Active
- 2000-05-15 AU AU45975/00A patent/AU777417B2/en not_active Expired
- 2000-05-15 CN CN00809976A patent/CN1360503A/zh active Pending
- 2000-05-15 PT PT00927584T patent/PT1176964E/pt unknown
- 2000-05-15 SK SK1644-2001A patent/SK287580B6/sk not_active IP Right Cessation
- 2000-05-15 MX MXPA01011562A patent/MXPA01011562A/es active IP Right Grant
- 2000-05-15 EP EP06011784A patent/EP1702618B1/fr not_active Expired - Lifetime
- 2000-05-15 CZ CZ20014081A patent/CZ301482B6/cs not_active IP Right Cessation
- 2000-05-15 DK DK00927584T patent/DK1176964T3/da active
- 2000-05-15 DE DE60045720T patent/DE60045720D1/de not_active Expired - Lifetime
- 2000-05-15 EP EP00927584A patent/EP1176964B8/fr not_active Expired - Lifetime
- 2000-05-15 DK DK06011784T patent/DK1702618T3/da active
- 2000-05-15 KR KR1020017014479A patent/KR20020019914A/ko not_active Ceased
- 2000-05-15 ES ES00927584T patent/ES2272279T3/es not_active Expired - Lifetime
- 2000-05-15 PL PL352931A patent/PL198185B1/pl unknown
- 2000-05-15 CN CNB2005100091622A patent/CN100477993C/zh not_active Expired - Lifetime
- 2000-05-15 TR TR2001/03819T patent/TR200103819T2/xx unknown
- 2000-05-15 SI SI200030905T patent/SI1176964T1/sl unknown
- 2000-05-15 NZ NZ515423A patent/NZ515423A/en not_active IP Right Cessation
- 2000-05-15 PT PT06011784T patent/PT1702618E/pt unknown
- 2000-05-15 SI SI200030977T patent/SI1702618T1/sl unknown
- 2000-05-15 AT AT06014005T patent/ATE500830T1/de active
- 2000-05-15 AT AT00927584T patent/ATE338552T1/de active
- 2000-05-15 AT AT06011784T patent/ATE375795T1/de active
- 2000-05-15 BR BR0010531-7A patent/BR0010531A/pt not_active Application Discontinuation
- 2000-05-15 DK DK06014005.0T patent/DK1716853T3/da active
- 2000-05-15 HU HU0201187A patent/HU229866B1/hu active Protection Beyond IP Right Term
- 2000-05-15 UA UA2001128559A patent/UA74782C2/uk unknown
- 2000-05-15 WO PCT/GB2000/001857 patent/WO2000069441A1/fr not_active Ceased
- 2000-05-15 DE DE60036826T patent/DE60036826T2/de not_active Expired - Lifetime
- 2000-05-15 ES ES06011784T patent/ES2294756T3/es not_active Expired - Lifetime
- 2000-05-15 PT PT06014005T patent/PT1716853E/pt unknown
- 2000-05-15 SI SI200031067T patent/SI1716853T1/sl unknown
2001
- 2001-11-11 IL IL146434A patent/IL146434A/en active Protection Beyond IP Right Term
- 2001-11-12 NO NO20015516A patent/NO324564B1/no not_active IP Right Cessation
- 2001-12-03 BG BG106171A patent/BG65680B1/bg unknown
2005
- 2005-01-14 AU AU2005200180A patent/AU2005200180B9/en not_active Expired
2006
- 2006-11-30 CY CY20061101734T patent/CY1105818T1/el unknown
2007
- 2007-06-28 US US11/769,873 patent/US8119638B2/en not_active Expired - Fee Related
2008
- 2008-01-16 CY CY20081100059T patent/CY1107143T1/el unknown
- 2008-02-22 NL NL300337C patent/NL300337I2/nl unknown
- 2008-03-10 LU LU91418C patent/LU91418I2/fr unknown
- 2008-04-07 CY CY200800007C patent/CY2008007I1/el unknown
- 2008-04-16 FR FR08C0013C patent/FR08C0013I2/fr active Active
- 2008-05-16 NO NO2008005C patent/NO2008005I1/no not_active IP Right Cessation
2011
- 2011-06-08 CY CY20111100545T patent/CY1112753T1/el unknown
2012
- 2012-05-02 JP JP2012105249A patent/JP5777562B2/ja not_active Expired - Lifetime
2015
- 2015-01-06 HU HUS1500001C patent/HUS1500001I1/hu unknown

Also Published As

Publication number	Publication date
DE60030554D1 (de)	2006-10-19
DK1176964T3 (da)	2007-01-15
DE60036826D1 (de)	2007-11-29
SI1716853T1 (sl)	2011-10-28
MXPA01011562A (es)	2002-07-30
DE60036826T2 (de)	2008-08-28
DE60030554T2 (de)	2007-09-13
BG106171A (en)	2002-06-28
HU229866B1 (en)	2014-10-28
DK1716853T3 (da)	2011-06-27
CY2008007I2 (el)	2009-11-04
SI1702618T1 (sl)	2008-02-29
AU2005200180B9 (en)	2008-05-29
EP1176964A1 (fr)	2002-02-06
SI1176964T1 (sl)	2007-02-28
LU91418I9 (fr)	2019-01-02
CY1105818T1 (el)	2011-02-02
UA74782C2 (uk)	2006-02-15
IL146434A0 (en)	2002-07-25
ATE375795T1 (de)	2007-11-15
NO20015516D0 (no)	2001-11-12
AU777417B2 (en)	2004-10-14
US20070275942A1 (en)	2007-11-29
MY164077A (en)	2017-11-30
CZ20014081A3 (cs)	2002-11-13
FR08C0013I1 (fr)	2008-05-30
EP1176964B1 (fr)	2006-09-06
CY1112753T1 (el)	2016-02-10
BR0010531A (pt)	2002-06-04
EP1716853A2 (fr)	2006-11-02
DE60045720D1 (de)	2011-04-21
DK1702618T3 (da)	2008-02-25
DE60030554T8 (de)	2008-01-10
IL146434A (en)	2008-03-20
CY1107143T1 (el)	2010-07-28
NL300337I1 (nl)	2008-05-01
NL300337I2 (nl)	2008-09-01
SK287580B6 (sk)	2011-03-04
ATE500830T1 (de)	2011-03-15
JP5777562B2 (ja)	2015-09-09
EP1716853B1 (fr)	2011-03-09
AU4597500A (en)	2000-12-05
ES2272279T3 (es)	2007-05-01
EP1716853A3 (fr)	2006-11-15
KR20020019914A (ko)	2002-03-13
AR028476A1 (es)	2003-05-14
EP1716853B9 (fr)	2011-09-28
AU2005200180A1 (en)	2005-02-10
DE122008000013I1 (de)	2008-08-07
CY2008007I1 (el)	2009-11-04
CA2373794C (fr)	2005-10-11
EP1702618B1 (fr)	2007-10-17
AU2005200180B2 (en)	2007-12-13
JP2012149095A (ja)	2012-08-09
LU91418I2 (fr)	2008-05-13
PT1716853E (pt)	2011-05-12
ATE338552T1 (de)	2006-09-15
WO2000069441A1 (fr)	2000-11-23
US8119638B2 (en)	2012-02-21
HUP0201187A2 (en)	2002-09-28
CN1360503A (zh)	2002-07-24
CN1679631A (zh)	2005-10-12
PL198185B1 (pl)	2008-06-30
JP2002544231A (ja)	2002-12-24
CN100477993C (zh)	2009-04-15
NO20015516L (no)	2002-01-11
NZ515423A (en)	2004-04-30
CA2373794A1 (fr)	2000-11-23
PT1702618E (pt)	2008-01-11
PL352931A1 (en)	2003-09-22
TR200103819T2 (tr)	2002-04-22
CZ301482B6 (cs)	2010-03-17
HUP0201187A3 (en)	2002-11-28
BG65680B1 (bg)	2009-06-30
NO2008005I1 (no)	2008-06-09
ES2294756T3 (es)	2008-04-01
HUS1500001I1 (hu)	2016-08-29
SK16442001A3 (sk)	2002-03-05
EP1702618A2 (fr)	2006-09-20
PT1176964E (pt)	2007-01-31
EP1176964B8 (fr)	2007-10-10
EP1702618A3 (fr)	2006-12-27
NO2008005I2 (fr)	2010-09-27
NO324564B1 (no)	2007-11-19

Publication	Publication Date	Title
HUS1500001I1 (hu)	2016-08-29	ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére
EE200100480A (et)	2002-12-16	Ksenoon kasutamiseks närvimürgistuste ravis
PT1147114E (pt)	2003-10-31	Novos aralquilaminas de espirofuropiridinas uteis em terapia.
EE05073B1 (et)	2008-10-15	Retigabiin kasutamiseks neuropaatilise valu ravis
DE60020327D1 (de)	2005-06-30	Wasserbehandlungsvorrichtung
PL370029A1 (en)	2005-05-16	2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
FI20020071A7 (fi)	2002-03-13	Applikaattori kõytettõvõksi refleksoterapiassa
GB0004167D0 (en)	2000-04-12	1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
ZA200108413B (en)	2003-03-26	Use of glycosyceramide synthesis inhibitors in therapy.
FI20020072A7 (fi)	2002-03-13	Applikaattori kõytettõvõksi refleksoterapiassa
IL147748A0 (en)	2002-08-14	Use of etodolac to treat cancer
HUP0300339A3 (en)	2009-01-28	Use of fulvestrant in the treatment of resistant breast cancer
GB9912159D0 (en)	1999-07-28	Improvements in and relating to the treatment of water
NO20014725L (no)	2001-11-13	Forbedret kreftbehandling med temozolomid
EP1242071A4 (fr)	2004-12-29	Utilisation du parthenolide pour inhiber le cancer
EE200200479A (et)	2003-12-15	Eksemestaani kasutamine rinnavähi ravis
MA24569A1 (fr)	1998-12-31	Inhibiteurs de farnesyl-transferase en association avec des inhibiteurs de hmg-coa-reductase pour le traitement du cancer
ZA200110436B (en)	2004-03-31	Therapeutic use of melatonin.
ID24405A (id)	2000-07-20	Pembnalut kesehatan yang dilengkapi dengan sayap
ATE302165T1 (de)	2005-09-15	Wasserbehandlung
ID30458A (id)	2001-12-06	Osanetan dalam pengobatan gangguan jiwa
NO20014228L (no)	2001-08-31	Radioaktiv cisplatin i behandling av cancer
FR2797183B1 (fr)	2002-03-08	Installation de massage pour le corps humain
HUP0105203A3 (en)	2002-08-28	S-nitrosothiols as agents for the treatment of circulatory dysfunctions and their use
FI20002612A0 (fi)	2000-11-28	Yhdistelmäterapia serotoniinivälityksen häiriöiden hoitamiseksi